ArticleJournal of biomedical research2025
Glycated albumin and composite glycemic-lipid indices: complementary tools for type 2 diabetes diagnosis.
Article in Journal of biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycated albumin (GA) is a promising glycemic biomarker that offers advantages over glycated hemoglobin (HbA1c), especially under conditions that affect red blood cell turnover. In type 2 diabetes (T2DM), disturbances in glucose and lipid metabolism often coexist. This study aimed at evalute the diagnostic utility of GA, HbA1c, and their composite indices incorporating high-density lipoprotein cholesterol (HDL-C) in a Serbian cohort. A total of 124 adults (including both T2DM patients and healthy controls) were analyzed for GA, HbA1c, glucose, and lipid profiles. Composite indices, namely, GA/HDL-C and HbA1c/HDL-C, were calculated. Logistic regression and ROC analyses were used to assess diagnostic performance. GA and HbA1c levels were significantly higher in T2DM patients, while HDL-C levels were lower. Both GA/HDL-C and HbA1c/HDL-C showed strong associations with T2DM. HbA1c exhibited the highest AUC (0.966), followed by HbA1c/HDL-C (0.883), GA/HDL-C (0.859), and GA (0.855). The GA/HDL-C index exhibited particularly high specificity (92.06%). GA levels in the control group were consistent with reference values reported in other populations, and this is the first study to provide GA data for a Serbian cohort. The findings highlight GA as a useful complementary marker for T2DM. Composite indices, particularly GA/HDL-C and HbA1c/HDL-C, offer enhanced specificity and may serve as simple, cost-effective tools for integrated metabolic risk evaluation and early T2DM detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.